TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 171 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $254,120 | -89.7% | 28,425 | -82.3% | 0.00% | -87.5% |
| Q2 2023 | $2,462,177 | -31.1% | 160,298 | +0.9% | 0.01% | -46.7% |
| Q1 2023 | $3,571,862 | +1093.1% | 158,820 | +1015.6% | 0.02% | +1400.0% |
| Q4 2022 | $299,383 | -72.8% | 14,236 | -68.2% | 0.00% | -83.3% |
| Q3 2022 | $1,102,000 | +216.7% | 44,723 | +211.4% | 0.01% | +200.0% |
| Q2 2022 | $348,000 | +9.8% | 14,363 | +9.9% | 0.00% | +100.0% |
| Q3 2021 | $317,000 | -62.6% | 13,069 | -77.5% | 0.00% | -66.7% |
| Q2 2021 | $848,000 | +11.3% | 58,130 | +90.5% | 0.00% | -25.0% |
| Q1 2021 | $762,000 | +64.2% | 30,509 | +79.3% | 0.00% | +33.3% |
| Q4 2020 | $464,000 | – | 17,013 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |